Skip to main content
VaccineWatch
VaccinesSymptomsStatesAnalysisToolsDashboardCompare

VaccineWatch

Transparent access to VAERS data for informed decision-making. We present the data as-is, with appropriate context and disclaimers.

Explore Data

  • Vaccines
  • Symptoms
  • Manufacturers
  • States
  • Dashboard
  • Compare Tool
  • Search

Deep Dives

  • The Denominator Problem
  • Onset Timing
  • Lot Number Analysis
  • COVID Impact
  • Myocarditis
  • Death Reports
  • Interactive Tools
  • All 23 Articles →

Resources

  • About
  • Methodology
  • FAQ
  • Glossary
  • Side Effects Guide
  • Vaccine Schedule
  • Vaccine Safety
  • Safety Timeline
  • Adverse Events
  • Is VAERS Reliable?
  • Report an Event
  • Disclaimer
  • VAERS Official Site ↗

Sister Sites

  • OpenMedicaid
  • OpenFeds
  • OpenSpending
  • OpenMedicare
  • OpenLobby
  • TheDataProject.ai

Data source: VAERS (Vaccine Adverse Event Reporting System)

Data through 2026 · Updated quarterly

Built by TheDataProject.ai · © 2026 VaccineWatch

Important: VAERS accepts reports of adverse events following vaccination. For any given report, there is no certainty that the reported event was caused by the vaccine. Reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. Most reports to VAERS are voluntary, which means they are subject to biases. This data cannot be used to determine if vaccines cause or contribute to adverse events.

⚠️

Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.

  1. Home
  2. Vaccines
  3. Influenza, Seasonal (Fluvirin)
  4. Disturbance in attention
Influenza, Seasonal (Fluvirin)×Disturbance in attention

Disturbance in attention Reports for Influenza, Seasonal (Fluvirin)

#377 most reported symptom for this vaccine

130
Reports
0
Deaths
18
Hospitalizations
0
Mortality Rate
%
13.8
Hosp. Rate
%

Disturbance in attention and Influenza, Seasonal (Fluvirin)

Disturbance in attention has been reported 130 times in association with Influenza, Seasonal (Fluvirin) vaccination in VAERS. This represents 0.1% of all 119,695 reports for this vaccine.

Among these reports, 0 mentioned death (0.00%) and 18 involved hospitalization (13.8%).

Disturbance in attention is the #377 most frequently reported symptom for Influenza, Seasonal (Fluvirin) out of 3021 total symptoms.

Disclaimer: VAERS reports describe events that occurred after vaccination but do not establish that the vaccine caused the event. Many reported symptoms may be coincidental or related to underlying conditions.

What This Means

Seeing 130 reports of Disturbance in attention after Influenza, Seasonal (Fluvirin) vaccination may seem alarming, but context is critical. With 119,695 total reports for this vaccine (representing many millions of doses), Disturbance in attention appears in only 0.1% of reports.

The mortality rate among these reports is very low at 0.00%, suggesting most cases are non-fatal.

Important Context

•Association, not causation: These reports show Disturbance in attention occurred after vaccination, not that the vaccine caused it.
•Background rates: Disturbance in attention may occur naturally at baseline rates in the population, unrelated to vaccination.
•Anyone can report: VAERS accepts reports from anyone — patients, parents, healthcare providers — without requiring medical verification.
•Denominator missing: VAERS counts reports, not rates per dose. Without knowing how many doses were given, raw counts can be misleading. Learn more →

Similarly Ranked Symptoms

Cardiac arrest130 reportsRespiratory failure130 reportsRed blood cell sedimentation rate130 reportsConstipation128 reports

Quick Facts

Reports:130
Deaths:0
Hospitalizations:18
% of Vaccine:0.1%
Rank:#377 of 3021

Related Pages

Influenza, Seasonal (Fluvirin) OverviewDisturbance in attention (All Vaccines)Why Raw Numbers MisleadTop Symptoms Analysis

Data Source

This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.